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Summary
Introduction. Diabetic retinopathy (DR) is a severe complication that can lead to complete vision loss and still is one of the main 
blindness-causing reasons among patients with type 1 diabetes mellitus (T1DM). DR as a complication can cause vision loss to 
people at their working age. More than 90% of patients with type 1 diabetes will develop DR by 20 years post diagnosis (Leslie 
R.Dye, 2018). DR is more likely to develop in patients with T1DM (Kanski’s Clinical Ophthalmology, 2016). This complication can
be very serious speaking of the ability to see. Sometimes vitrectomy plays a vital role in the management of severe complications
of DR at its end-stage (Myron Yanoff et al., 2020).
Aim of the study. To prove the development severity of DR that depends on the duration of diabetes and metabolic compensation. 
Additionally, to determine retinopathy’s association with other micro and macrovascular diabetes mellitus complications for a
better understanding of what are the contributory factors for these complications to develop and which of those may coexist.
Materials and Methods. A retrospective study was held at the Pauls Stradins Clinical University Hospital (Riga, Latvia). From
January 2016 to March 2018, 79 (158 eyes) patient histories were analyzed who have type 1 diabetes mellitus. To obtain more
precise research results, almost all patients have done check-up visits to one certain ophthalmologist.  The IBM SPSS Statistics
version 25.0 was used to process data. Tables were made in SPSS and Microsoft Excel 2016 programs. Statistically significant
value (p) was set at < 0,05.
Results. No statistically significant difference is seen in the mean duration of the disease: in the group of proliferative diabetic
retinopathy (PDR):  25.23 (median = 22.0) years and non-proliferative group: 24.68 (median = 23.50) years. Results show that the
duration of diabetes mellitus is considerably smaller in a group without DR 11.24 (median = 8.50) years. Metabolic compensation
(%) in diabetes mellitus is not statistically different between patients with diverse forms of DR; no association found either. No
statistically significant difference in best corrected visual acuity (BCVA) was detected among patients with various forms of DR.
Three groups were compared: both types of DR and no DR. It was detected that BCVA in patients without DR was higher in both
eyes: 0.83 ± 0.27 dioptres. No statistically significant difference (pχ > 0.05) was detected between the groups of DR and therefore
no association was made between the form/existence of DR and arterial hypertension. There is a strong association between DR
and microvascular complications (V = 0.40) with the existence of DR and there is an even stronger association (V = 0.61) with the
forms of DR.  There is no statistically reliable difference (pχ > 0.05) between the groups of DR; therefore, no association with the
existence of microvascular complications and also risk factors.
Conclusions. More than two-thirds of patients included in the research have some signs of DR. Because of the strong association 
of DR and other microvascular complications, patients with diabetes should be screened regularly for retinopathy, nephropathy,
and neuropathy. And likewise, if a patient has at least one microvascular complication, he or she should be tested for the
rest possible complications as well. According to data, most of the patients in this study have poor metabolic compensation;
consequently, the metabolic compensation screening should be done certainly every three months.
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INTRODUCTION
Diabetic retinopathy (DR) is a severe complication of 
diabetes mellitus (DM) that can cause vision loss to 
people at their working age. More than 90% of patients 
with type 1 diabetes mellitus (T1DM) will develop DR 
by 20 years post diagnosis (Leslie R.Dye, 2018). DR is 
more likely to develop in patients with T1DM (Kanski’s 
Clinical Ophthalmology, 2015). Other microvascular 
complications coexist with DR such as diabetic 
neuropathy and especially diabetic nephropathy (Leslie 
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RESULTS
Altogether 79 patient histories were analysed from 
which 38 (48.10 %) were men, and 41 (51.90%) were 
women. The mean age of 79 patients was 40.01 ± 14.10 
years with the interval from 19.00 to 76.00 years of 
age (Fig. 1). This range was not in normal distribution 
(median = 37.0). Out of 78 patients the mean duration 
of diabetes was 21.77 ± 12.08 years with an interval
of less than 1.00 year to 49.00 years of the disease 
(Fig. 2). This range is in normal distribution (median 
= 20). The mean value of metabolic compensation of 
diabetes was 9.55% ± 1.82%, with intervals of 5.50%
to 14.70%. This range was not in normal distribution 
(median = 9.30) (Fig. 3).
DR was detected in most of the patients – 61 or 79.22%. 
Analysing this group further, we have concluded that 
23 or 29.11% from all the patients have (PDR) (Fig. 
4), whereas 38 or 48.10% – non–proliferative diabetic 
retinopathy NPDR (Fig. 5). For the smallest part – 16 
or 20.25% patients DR were not detected (Fig. 6). Two 
patients or 2.53% did not have information whether 
they have or do not have DR, so they were excluded 
from further study. 
No statistically significant difference can be detected 
in the mean indicator of the duration of disease; 
however, the duration of DM is considerably smaller in 
a group without DR (11.24, median = 8.50). Analysing 
2 groups separately and using Mann–Whitney test, no 
statistically significant difference in the mean duration 
of the disease is seen (p > 0,05, η = 0.02). Analysing
between 3 groups, it is evident that the duration of 
diabetes in group without DR is significantly smaller 
and the difference is statistically significant (p < 0.05) 
and association is moderately tight (η = 0.46), as
indicated in Fig. 7.
Metabolic compensation (%) in diabetes mellitus is 
not statistically different between patients with diverse 
forms of DR, so no association was found (p > 0.05). 
No statistically significant difference has been detected 
comparing visual acuity for the right and left eye 
among patients with various forms of DR. However, 
when comparing the three groups (both types of 
DR and no DR), in patients without DR the visual 
acuity was higher in both eyes: 0.83 ± 0.27 dioptres.
Difference between the groups is statistically significant 
(p <0.05) for both eyes. Analysing association between 
DR and VA (visual acuity) it was detected that for the 
right eye it was higher or more precise also it was 
moderately tight (η = 0.45), but for the left eye – weak
or eta was 0.34 (Fig. 8). From all patients who had 
information whether they have or not have arterial 
hypertension, altogether 77, the presence of this 
disease was noticed in 24 or 31.17% of patients. 53 or 
68.83% did not have the condition. Analysing further 
the form or existence of DR with the presence of AH, 
it was found out that there is no statistically credible 
difference (p
 
> 0.05) between the groups and no 
statistically significant association either. Also, another 
R.Dye et al., 2018). From about 285 million of inhabitants 
who suffer from DM, one third have first signs of DR;
two–thirds have vision–threatening DR including
macular oedema. The leading role in the pathogenesis
of DR is AH (arterial hypertension) and hyperglycemia
which develops from longstanding inflammation and
oxidative stress in tissues (Ryan Lee et al., 2015).
The combination of these factors leads to gradually
progressive changes in retinal microvasculature causing 
mal–bloodied or even ischemic areas in the retina
and, elevated permeability, which leads to exudation
in the retina or further – macular oedema. Regarding
ischemic regions in the retina, new vasculature starts
to develop. From this point, proliferative diabetic
retinopathy (PDR) develops which can lead to
irreversible vision loss if it is not detected and treated
as early as possible (Shlomo Melmed et al., 2016.). This
complication can be very serious in terms of the ability
to see. Sometimes vitrectomy plays a vital role in
the management of severe complications of diabetic
retinopathy at its end–stage. The major indications
are non–clearing vitreous haemorrhage, macular–
involving or macular–threatening traction retinal
detachment, and combined traction–rhegmatogenous
retinal detachment (Myron Yanoff et al., 2020). Although
nowadays there are many therapeutic options, the
main goal is to prevent complications from occurring,
that is why we are concentrating on variable disease
factors and how to use them for a more extended
period without complications.
AIM OF THE STUDY
To prove the development severity of diabetic 
retinopathy that depends on the duration of diabetes 
and metabolic compensation. Also, to determine 
retinopathy’s association with other micro and 
macrovascular DM complications for a better 
understanding of what are the contributory factors for 
these complications to develop and which of those may 
coexist.
MATERIALS AND METHODS
In a retrospective study held at the Pauls Stradins 
Clinical University Hospital (Riga, Latvia) from January 
2016 to March 2018, 79 (158 eyes) patient histories 
were analyzed who have type 1 diabetes mellitus. 
To obtain more precise research results, almost all 
patients have done check–up visits to one certain 
ophthalmologist. The IBM SPSS Statistics version 25.0 
was used to process data. Tables were made in the SPSS 
and Microsoft Excel 2016 programs. For distribution 
probability Kolomogorov–Smirnov and Shaipro–Wilk 
test was used. Chi–Square test was used to determine 
difference and Cramer V measure was applied for 
association between groups. Also, Mann–Whitney an 
Kruskal–Walis tests were used. To describe strength of 
association, eta (η) was used. Statistically significant
value (p) was set at < 0.05 or 5.00 x10–2.
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of DM most of the patients did not have any signs of 
DR (as confirmed in Abdish R Bhavasar, MD et al., 2017), 
because it is known that the first–time diagnostics of 
T1DM more often occurs in the early age of puberty, 
and patients up to 18 years of age mostly are examined 
by the child ophthalmologist. This data was missing in 
our research. Metabolic compensation a.k.a. HbA1c 
level is not statistically different between patients with 
distinct forms of DR. Also, compared to a group with 
patients who do not have DR, statistically reliable 
difference was not obtained between the mean values 
of HbA1c in the three groups, because the mean value 
of metabolic compensation in both types of DR and also 
no DR is almost identical. In scientific literature where 
the metabolic compensation’s association with DR was 
examined, for example, in Chawla et al., 2014, it was 
stated that maximal values of metabolic compensation 
were seen in the following groups: (1) NPDR and (2) 
a group with no signs of DR. Temporary glycemic 
fluctuations do not affect this value, but it is known 
that retinal blood vessels are susceptible to these kind 
of changes, for example, hypoglycemic episodes. 
Therefore, more extensive research would determine 
how many hypoglycemic episodes each person has 
had. This value could be associated with the severity 
of DR. Presumably that HbA1c value is more likely to 
be useful if we investigate type 2 DM patients because 
in these cases glucose level does not tend to fluctuate 
as much as in T1DM patients. As it is said in The global 
diabetes community, 2018 HbA1c is very crucial to be 
<6.5%, because it protects from the development of 
microvascular complications as diabetic retinopathy. 
Comparing BCVA for the right and the left eye in 
patients with diverse forms of DR in Fig. 6 we see that 
there is no statistically significant difference in the 
mean visual acuity. This means that in both forms of 
DR deteriorated visual acuity can be detected, which 
in both cases according to the World Health Organization 
visual deterioration classification (evaluating the eye 
with the best–corrected visual acuity) ranks close to a 
normal value of visual acuity (0.6–0.3). If a comparison 
is made between the three groups (Fig. 8; both forms 
with DR and no DR), it becomes evident that BCVA 
in patients without DR is noticeably higher in both 
eyes, which rank this value as normal. Probably the 
cause for deterioration of eyesight is one of the DR 
stages, but it is not unequivocally, because some 
of the patients might have had other eye diseases 
that are not detailed in this research. Analyzing the 
form of DR and its association with the presence or 
stages of AH, no statistically significant difference (p 
> 0.05) between the groups and no significant direct
association between AH and stages of DR were found.
AH is a secondary risk factor, which may worsen
the development of DR by causing hypertensive
vascular changes in retina, furthermore worsening
the blood flow (Abdish R Bhavasar, MD et al., 2017). The
presence of AH is more important when DR is already
developed. Correction of AH is crucial because it can
reduce the diabetic nephropathy from developing, as
microvascular complication was analysed including 
nephropathy (2 patients or 2.60%), polyneuropathy 
(25 or 32.47%), or both forms together (22 or 
29.87%). One group without any other coexisting 
microvascular complications was set (27 or 35.06%). 
Between DR and microvascular complications strong 
association (p <0.05, V=0.61) with the existence of 
DR and even stronger association (p
 
< 0.05, V=0.40) 
was found with the forms of DR. So we can see that in 
patients with diabetic non–prolipherative retinopathy 
(DNR) more often polyneuropathy or combination 
of both microvascular combination appears. Diabetic 
prolipherative retinopathy (DPR) patients does not 
have other microvascular complications whether have 
both complications at the same time. Furthermore, 
nephropathy separately was seen only in patients with 
DPR or without DR (Fig. 9). 
Most of the patients – 59 or 76.62% – did not have 
any of macrovascular complications (atherosclerosis, 
dyslipidemia, or coronary artery disease). Only four 
patients had some of the macrovascular complications: 
three had atherosclerosis and coronary artery disease, 
whereas one had dyslipidemia and coronary artery 
disease. Further analysis revealed that there was no 
statistical significance (p > 0.05) between the groups and 
thereby no significant association was made between 
the groups of DR and macrovascular complications. 
DISCUSSION
No statistically significant difference can be detected in 
the mean indicator of duration of the disease because 
in these two groups the mean indicator of duration 
is very similar. In this particular case, we cannot 
unequivocally prove the previously mentioned fact 
that “longer duration of diabetes means more severe 
DR” by Shlomo Melmed et al., 2016. Probably to prove 
the fact, more extensive research should be carried out 
comparing each patient’s duration of disease with the 
type of DR and its stage/severity with a greater amount 
of patients. If we compare the three groups (both types 
of DR and no DR), it can be seen that the duration 
of DM in patients without DR is much shorter. This 
data corresponds with the previously mentioned 
facts that after 20 years in almost all diabetes mellitus 
type 1 patients some DR is seen. Regarding those 
patients included in research, any kind of DR stage is 
determined whether it is NPDR or PDR for those who 
have more than 20 years of diabetes. It also confirms 
the fact that in a group where the mean duration of 
diabetes is 11.24 years, no DR signs were yet detected 
like it was mentioned in Abdish R Bhavasar, MD et al., 
2017 publication. As it was stated in  Shlomo Melmed et 
al., 2016, after ten years of diabetes, incidence of DR 
development risk can reach even 60 % among patients 
with type 1 DM. This association is visualized in Figures 
2 and 7 where it can be seen that most patients with 
a duration of DM longer than ten years also have an 
incidence of any kind DR – 61 or 79.22% patients. 
Unfortunately our research was limited, since we 
could not specify whether five years after diagnosis 
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CONCLUSIONS
More than two–thirds of patients included in the 
research herein have some signs of DR. Patients who do 
not have any signs of DR have a shorter mean duration 
of DM than those who have either proliferative or 
nonproliferative DR. The results partially correspond to 
the data from other scholarly sources. No statistically 
positive difference was found between the forms of 
DR and the mean values of metabolic compensation, 
although the association is mentioned in other scholarly 
sources. Comparing the two groups (both types of DR 
and no DR), it was detected that VA in patients without 
DR was higher in both eyes. No statistically significant 
difference and association were found between the 
type or existence of DR and AH. The results of the 
research show that microvascular complications of 
diabetes mellitus have a strong association with the 
presence of DR and even stronger with the forms of 
DR. Consequently, patients with diabetes should be 
screened regularly for retinopathy, nephropathy, and 
neuropathy. Furthermore, if a patient has at least 
one microvascular complication, he or she should be 
tested for the rest possible complications as well. No 
significant association was found between the form/
existance of DR and macrovascular complications and 
the risk factor – AH.
Conflict of interest: None
it is mentioned in Europe’s prospective research of diabetic 
complications, 2013. Examining the association between 
DR and microvascular complications, as seen in Fig. 
9, it can be concluded that these complications have 
a strong association with the presence of DR and even 
stronger with the form of it as mentioned in the sources 
of literature. Many associations between microvascular 
complications and DR, and also with each other are 
mentioned in many scientific studies. 
For example, in Aastha Chawla, 2016 publication it is 
mentioned that nephropathy was detected to 15–
40% among T1DM patients. In the research herein, 
nephropathy was detected to 22 patients making 
17.38%, which is very similar. Speaking of other 
microvascular complication – polyneuropathy in Aastha 
Chawla, 2016 publication it is stated that almost half of 
patients have it. According to the research herein, 47 
patients have this complication constituting 59.49% 
and making up the majority. Consequently, this data 
corresponds to the data in other studies. Furthermore, 
in Aastha Chawla, 2016 publication it is mentioned that 
the risk for DR to develop is directly proportional to 
the duration of DM and severity of hyperglycemia. 
Pursuant to the research herein, majority of patients 
have the duration of DM 10, 15 and more years. Also, 
association with values of metabolic compensation 
is seen because the majority had poor and very poor 
metabolic compensation. The majority of patients 
were in a group that had a metabolic compensation 
value of more than 10% while the preferred value 
is ≤ 7%. Analyzing if macrovascular complications/
existence of risk factors have an association with the 
existence of DR, we can conclude that there is no 
statistically significant difference between the groups 
and also no statistically significant association between 
these groups of DR and macrovascular complications. 
Therefore, in this case we cannot agree with Krentz et al., 
2007 and Al–Wakeed et al. 2009 studies in which it is said 
that micro and macrovascular complications develop 
simultaneously. Also, no parallels have been detected 
with Matheus and Gomes, 2013 publication where it is 
stated that aggressive coronary disease developed 
in patients without microvascular complications. 
Although a patients group with macrovascular 
complications was very small after all. 
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Fig. 4. Fundus photograph shows PDR with 
laser photocoagulation scars along blood vessel 
arcades. Upwards and downwards from optic 
disc fibrovascular membranes and underneath 
vascular tortuosity. Neovascularisation in 
the upper nasal quadrant. Grainy macular 
appearance, perimacular hard exudates, various–
size dot–blot haemorrhages in all quadrants
Fig. 5. Fundus photograph shows NPDR with 
multiple dot–blot and flame–like haemorrhages 
in the macula and along temporal blood vessel 
arcades, cotton–wool spots along inferior blood 
vessel arcade and groups of hard exudates 
temporally from the macula
Fig. 1. Patient’s age distribution in groups
Fig. 2. Duration of diabetes mellitus distribution
Fig. 3. Metabolic compensation values 
distribution
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Fig. 9. DR coexistence and association with other 
microvascular complications among different 
types of DR and group without DR.
Mean visual accuity shown on the poles 
depending on the type of DR.
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